Zydus Lifesciences, a renowned global pharmaceutical company, has achieved a significant milestone by completing the enrollment for the Phase II clinical trial of its novel oral NLRP3 inflammasome inhibitor, Usnoflast (ZYIL1), aimed at treating patients with Amyotrophic Lateral Sclerosis (ALS). This development marks a pivotal step in addressing the urgent need for effective treatments in […]
Zydus Lifesciences, a discovery-based, global pharmaceutical leader, has recently received approval from the World Health Organization (WHO) International Non-proprietary Names (INN) for “Usnoflast” as the recommended name for ZYIL1, marking a significant milestone in the development of treatments for neuroinflammatory and autoinflammatory diseases. Usnoflast (ZYIL1) is an innovative oral small molecule NLRP3 inhibitor, showcasing high […]
